Outlook Therapeutics, Inc.
ONS-5010
bevacizumab-vikg
Countdown
23days
FDA decision · Jul 29, 2026
What's at stake
The FDA's approval decision on ONS-5010 for bevacizumab-vikg is due Jul 29, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 13h ago
“The FDA set a Prescription Drug User Fee Act (PDUFA) goal date of July 29, 2026.”